Question 1

What does the 77.48% retention rate for SVF breast augmentation mean?

Accepted Answer

The 77.48% figure comes from a 2023 study in Annals of Plastic Surgery authored by SC301's representative director: among 384 women who had SVF-enriched breast fat grafting, the average retention measured in the left breast was 77.48% in the 102 patients followed to 18 months. It is a single-center, provider-authored result, not a general average for all SVF fat grafting, and should be read with its study design.

Question 2

Who is suitable for SVF breast augmentation?

Accepted Answer

Candidates are generally healthy adults who want a modest, natural increase in breast size, have enough donor fat for liposuction, and accept that a portion of the graft will be resorbed and that repeat sessions may be needed. People wanting a large increase, with very little body fat, or with conditions affecting healing may be better served by other options. A surgeon's assessment is required.

Question 3

SVF 가슴성형 상담 전 준비할 것, 무엇이 있나요?

Accepted Answer

상담 전에는 세 가지를 준비하는 것이 좋습니다. 첫째, 본인의 병력과 유방 검사 자료입니다. 둘째, 원하는 부피와 지방을 채취할 부위에 대한 정보입니다. 셋째, 기관에 물어볼 확인 질문 목록입니다. 특히 물어볼 내용은 세포 처리의 규제상 지위, 담당 의사가 전문의인지, 생착률 측정 방법과 자료의 출처, 비용 포함 항목, 재이식 조건입니다.

Question 4

韓国のSVF豊胸で言われる「定着率77%」は、どの論文の何の数字ですか？

Accepted Answer

SC301が執筆した単一施設の症例集積に由来する数値で、平均注入量162.35 mL（左乳房）に対し3か月78.65%、6か月77.17%、18か月77.48%（n=102）と報告されています[1]。別の2020年の報告では105例で1か月85.1%、3か月75.1%、6か月73.7%でした[2]。いずれも対照群がなく、著者が施術提供側に所属する論文です。日本で一般に言われる「脂肪注入の生着率」と同じ条件で測った数値ではないため、単純比較はできません。

Question 5

幹細胞（SVF）を混ぜると、普通の脂肪注入豊胸より本当に定着率は上がるのですか？

Accepted Answer

独立したメタアナリシスの結論は一致していません。豊胸を対象とした解析（6研究・353例）ではCAL全体で生着が高い（SMD 1.79、95% CI 0.28–3.31）一方、合併症に有意差はなく（OR 1.34）、SVFを添加したサブグループに絞ると生着率の差は認められませんでした[1]。部位を限定しない15研究の解析では細胞添加群が有利（SMD 2.44）でしたが、異質性がI² = 97.19%と極めて高く、効果は条件依存とされています[2]。

Question 6

韓国でのSVF豊胸の費用はいくらですか？日本との差はどれくらいですか？

Accepted Answer

ここで参照している出典は学術論文と規制当局の資料であり、韓国・日本いずれの価格も掲載されていません。したがって当ページでは金額を示せません。見積もりを取る際は、脂肪吸引部位の数、SVF分離にかかる費用が別建てか、麻酔・入院・術後検診・再注入が総額に含まれるかを書面で確認してください。価格差の比較は、同じ内容が含まれているかを揃えないと意味を持ちません。

Question 7

日本では同じSVF豊胸を受けられますか？厚生労働省やPMDAの扱いはどうなっていますか？

Accepted Answer

日本でも細胞を加工して用いる医療は提供できますが、再生医療等安全性確保法の枠組みで、リスク分類に応じた提供計画の提出と認定再生医療等委員会の審査が必要です。これは届出の制度であって「厚生労働省の承認」ではありません。承認された再生医療等製品かどうかはPMDAの情報で確認できます。実際に受けられるかは医療機関ごとに異なるため、提供計画の番号と審査した委員会名を確認してください。

Question 8

2025年2月施行の韓国の再生医療の法律で、外国人でもSVF豊胸を受けられるのですか？

Accepted Answer

韓国では첨단재생바이오법（先端再生バイオ法、先端再生医療・先端バイオ医薬品に関する法律）の改正が2025年2月21日に施行され、再生医療の「治療」は重篤・希少・難治性疾患に限り、指定された医療機関で、審議委員会が治療計画を承認した場合にのみ提供できる枠組みになりました[1]。この出典は、美容目的のSVF添加脂肪注入がこの枠組みのどこに位置づけられるかまでは述べていません。渡航前に、その施設がどの法的枠組みで当該施術を提供しているのかを直接確認してください。

Question 9

SVF豊胸のあと、しこりや石灰化はできますか？帰国後の乳がん検診に影響しますか？

Accepted Answer

報告はあります。40例のシリーズではMRIで12 mm未満の嚢胞が2例、術後24か月のマンモグラフィで微小石灰化が2例ありました。総説では嚢胞形成の頻度として自動分離6.9%、用手分離1.6%が引用されています。日本の学会の治療手順では、こうした所見が乳房画像で乳がんと紛らわしくなる場合があるとされ、長期の経過観察が勧められています。帰国後の検診では施術内容と時期を必ず伝えてください。

Question 10

アメリカではSVFが規制されていると聞きましたが、どういう経緯ですか？

Accepted Answer

米国FDAは2017年8月24日の警告書で、脂肪由来SVFは21 CFR 1271.10(a)(1)の「最小限の操作」基準を満たさず、医薬品・生物学的製剤としてINDまたは承認済みBLAが必要との立場を示しました[1]。その後2024年9月、第9巡回区控訴裁判所は同日施術の例外（same-surgical-procedure exemption）はSVF施術に適用されないと判断し、2025年10月15日に連邦最高裁が上告審理を受理しませんでした[2]。

항목	값	출처
Definition	Autologous fat grafting in which SVF isolated from part of the aspirated fat is recombined with the remaining fat before injection, turning progenitor-poor aspirated fat into progenitor-rich fat	[3]
First described for cosmetic breast augmentation	Yoshimura K et al., Aesthetic Plastic Surgery 32(1):48–55 (2008); 40 patients, mean ~270 mL fat injected per breast, final gain 100–200 mL기준 2008년 1월 1일	[3]
Complications in original series	Cysts (<12 mm) on MRI in 2 patients; microcalcification on mammogram in 2 patients at 24 months; 1 case of sternal fibrosis기준 2008년 1월 1일	[3]
Breast augmentation meta-analysis (Li & Chen)	6 studies, 353 patients: CAL had higher fat survival (SMD 1.79, 95% CI 0.28–3.31); complications did not differ significantly (OR 1.34); the SVF-enriched subgroup showed no survival difference기준 2021년 8월 1일	[4]
Meta-analysis across recipient sites (Sutar et al.)	15 studies: graft survival favored enriched grafts (SMD 2.44), with very high heterogeneity (I² = 97.19%); benefit was context-dependent기준 2026년 1월 1일	[5]
US FDA position	Adipose-derived SVF fails the minimal-manipulation criterion (21 CFR 1271.10(a)(1)) and needs an IND or an approved BLA as a drug/biologic기준 2017년 8월 24일	[6]
US court ruling on same-day SVF	Ninth Circuit (Sept 2024) held SVF procedures do not qualify for the same-surgical-procedure exemption; the Supreme Court declined review on 2025-10-15기준 2025년 10월 15일	[7]
Korea: Advanced Regenerative Bio Act amendment	Effective 2025-02-21: regenerative-medicine treatment allowed only for serious, rare or intractable diseases, at designated institutions, with review-committee approval of treatment plans기준 2025년 2월 21일	[8]
Reported safety concerns	Cyst formation 6.9% with automated vs 1.6% with manual isolation in cited data; theoretical oncogenic concern from VEGF/FGF signalling; long-term oncologic data insufficient기준 2022년 3월 2일	[9]
Method standardization	No standardized CAL protocol; multiple isolation systems in use (e.g., Celution, Medikhan, Fatstem, Mystem)기준 2022년 3월 2일	[9]
Reported outcome (SC301-authored, 2023)	Average injected volume 162.35 mL (left breast); retention 78.65% (3 mo), 77.17% (6 mo), 77.48% (18 mo, n=102)기준 2023년 4월 1일	[1]
Reported outcome (SC301-authored, 2020)	In 105 patients, engraftment 85.1% (1 mo), 75.1% (3 mo), 73.7% (6 mo); patients receiving >60 million ADSC had 90.5% vs 68.9% for <60 million기준 2020년 2월 7일	[2]
Evidence level	Single-center, provider-authored series; no independent randomized controlled data identified as of 2026-09기준 2026년 9월 14일	확인 중

주장	유형	근거	출처
In a 384-patient single-center series, average retention after SVF-enriched breast fat grafting was 77.48% at 18 months (n=102). Peer-reviewed but provider-authored, no control group; retention measured in left breast; conflicts of interest declared none.	statistic	제한적 SC301 (author-affiliated)	A Study on Breast Augmentation Using Fat Grafting With Stromal Vascular Fraction (Shin DJ, Ann Plast Surg 2023;90(4):380-384)
Higher SVF cell number and softer breast tissue were associated with higher retention.	outcome	제한적 SC301 (author-affiliated)	A Study on Breast Augmentation Using Fat Grafting With Stromal Vascular Fraction (Shin DJ, Ann Plast Surg 2023;90(4):380-384)

SVF Breast Augmentation

What does the 77.48% retention rate for SVF breast augmentation mean?

핵심 사실

개요

검증 프로바이더

SC301의원

근거와 주장

참고 출처

What does the 77.48% retention rate for SVF breast augmentation mean?

핵심 사실

개요

관련 엔티티

관련 질문

검증 프로바이더

SC301의원

근거와 주장

참고 출처